ICU Medical, Inc. $ICUI Stock Holdings Lowered by Rhumbline Advisers

Key Points

• Rhumbline Advisers has reduced its stake in ICU Medical, Inc. by 4.5%, now holding 64,822 shares valued at approximately $9 million.
• Institutional investors own a significant majority, 96.10%, of ICU Medical's stock, reflecting strong interest from large financial firms.
• ICU Medical reported an earnings per share of $2.10 for the last quarter, surpassing expectations and illustrating resilience despite an 8% revenue decline year-over-year.

Rhumbline Advisers lowered its position in shares of ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 4.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 64,822 shares of the medical instruments supplier's stock after selling 3,069 shares during the quarter. Rhumbline Advisers owned 0.26% of ICU Medical worth $9,001,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Ameriprise Financial Inc. raised its holdings in shares of ICU Medical by 18.5% during the first quarter. Ameriprise Financial Inc. now owns 693,711 shares of the medical instruments supplier's stock valued at $96,326,000 after acquiring an additional 108,493 shares during the period. Point72 Asset Management L.P. raised its holdings in shares of ICU Medical by 63.2% during the fourth quarter. Point72 Asset Management L.P. now owns 245,340 shares of the medical instruments supplier's stock valued at $38,069,000 after acquiring an additional 95,030 shares during the period. Invesco Ltd. raised its holdings in shares of ICU Medical by 80.1% during the first quarter. Invesco Ltd. now owns 203,827 shares of the medical instruments supplier's stock valued at $28,303,000 after acquiring an additional 90,674 shares during the period. Woodline Partners LP raised its holdings in shares of ICU Medical by 31.6% during the first quarter. Woodline Partners LP now owns 160,910 shares of the medical instruments supplier's stock valued at $22,344,000 after acquiring an additional 38,671 shares during the period. Finally, Victory Capital Management Inc. raised its holdings in shares of ICU Medical by 5.7% during the first quarter. Victory Capital Management Inc. now owns 149,246 shares of the medical instruments supplier's stock valued at $20,724,000 after acquiring an additional 8,101 shares during the period. Institutional investors and hedge funds own 96.10% of the company's stock.

ICU Medical Stock Performance

ICUI stock opened at $133.57 on Thursday. The company has a quick ratio of 1.17, a current ratio of 2.44 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $3.30 billion, a price-to-earnings ratio of -87.87 and a beta of 0.86. ICU Medical, Inc. has a 12 month low of $107.00 and a 12 month high of $196.26. The firm has a 50 day moving average of $126.34 and a two-hundred day moving average of $134.19.

ICU Medical (NASDAQ:ICUI - Get Free Report) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $2.10 EPS for the quarter, topping the consensus estimate of $1.44 by $0.66. The company had revenue of $543.57 million during the quarter, compared to the consensus estimate of $543.33 million. ICU Medical had a negative net margin of 1.56% and a positive return on equity of 7.24%. The company's revenue for the quarter was down 8.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.56 earnings per share. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. As a group, equities analysts anticipate that ICU Medical, Inc. will post 4.11 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on ICUI shares. Wall Street Zen upgraded shares of ICU Medical from a "hold" rating to a "buy" rating in a report on Friday, September 5th. Piper Sandler upped their price objective on shares of ICU Medical from $145.00 to $153.00 and gave the company an "overweight" rating in a research note on Wednesday. Finally, Raymond James Financial dropped their price objective on shares of ICU Medical from $187.00 to $180.00 and set a "strong-buy" rating on the stock in a research note on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, ICU Medical presently has an average rating of "Buy" and an average target price of $181.00.

Insider Buying and Selling at ICU Medical

In other news, CEO Vivek Jain acquired 21,929 shares of the firm's stock in a transaction that occurred on Thursday, August 14th. The stock was acquired at an average cost of $112.84 per share, with a total value of $2,474,468.36. Following the acquisition, the chief executive officer owned 130,149 shares in the company, valued at approximately $14,686,013.16. This represents a 20.26% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director David C. Greenberg acquired 1,200 shares of the firm's stock in a transaction that occurred on Wednesday, August 27th. The shares were purchased at an average cost of $126.42 per share, with a total value of $151,704.00. Following the completion of the acquisition, the director owned 7,960 shares in the company, valued at $1,006,303.20. This trade represents a 17.75% increase in their position. The disclosure for this purchase can be found here. 1.50% of the stock is currently owned by corporate insiders.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.